TechValidate Research on Philips Respironics: Trilogy Ventilator

These pages present data that TechValidate has sourced via direct research with verified customers and users of Philips Respironics: Trilogy Ventilator. TechValidate stands behind the authenticity of all published data. Learn more »



786 Customers Surveyed

5,037 Data Points Collected

25 Published TechFacts

6 Published Charts

3 Published Case Studies



Selected Research Highlights


Philips Respironics: Trilogy Ventilator Customer Research

What benefits has the Trilogy provided for your patients?

Ease of use
82%
Improved quality of life
80%
Reduced hospital readmissions
68%
Clinical efficacy
65%
Increased patient adherence to therapy
63%

Philips Respironics: Trilogy Ventilator Customer Research

What were the top purchasing drivers when buying the Trilogy for your organization?

Trilogy product quality and reputation
58%
Physician scripted/preference
25%
AVAPS AE specifically for the COPD population
49%
Improving patient outcomes
54%
Philips brand
18%

Philips Respironics: Trilogy Ventilator Customer Statistic

79% of healthcare organizations agreed with the following statement:

“When transitioning sensitive children from their critical care ventilator, Trilogy with Auto-Trak is the most effective ventilation choice for positive outcomes.”

Case Study: Medium Enterprise Health Care Company

Introduction

This case study of a medium enterprise health care company is based on a November 2014 survey of Philips Respironics: Trilogy Ventilator customers by TechValidate, a 3rd-party research service. The profiled company asked to have their name blinded to protect their confidentiality.

“Has given us the ability to keep patients out of the hospital by using Trilogy AVAPS-AE in our NIV program targeted at reducing hospital readmissions.”

Challenges

  • Purchased the Trilogy because of:
    • The Trilogy product quality and reputation
    • AVAPS AE specifically for the COPD population
    • A need to improve patient outcomes
  • Looking to achieve the following challenges with the Trilogy:
    • Reduce the amount of time managing difficult patients
    • Improve patient satisfaction

Use Case

  • 50-74% of their Trilogy devices are brand specific prescriptions from a Pulmonologist or Physician.
  • Greater than 75% of their Trilogy patients are diagnosed with COPD.
  • Evaluated the following alternative devices before purchasing the Trilogy:
    • ResMed Astral
    • ResMed Stellar
    • LTV
  • AVAPS AE is the most commonly prescribed mode for Non-Invasive Ventilation COPD patients.

Results

  • Patients realized the following benefits with the Trilogy:
    • Provided ease of use
    • Improved quality of life
    • Improved clinical efficacy
    • Reduced hospital readmissions
    • Increased patient adherence to therapy
  • Decreased hospital re-admissions for COPD patients by greater than 75% with the Trilogy with AVAPS AE.
  • Rates the following Trilogy capabilities on how differentiated they are from the competition:
    • clinical performance: differentiated
    • ease of use: differentiated
    • reliability: differentiated
    • patient satisfaction: differentiated
    • ventilation modes (AVAPS AE): highly differentiated

Philips Respironics: Trilogy Ventilator Customer Testimonial

My 60 + patient load has shown to have decreased hospital admissions, improved quality of life, and an overall positive effect on their every day lives. In addition, the doctors like the reports I send them on a monthly basis.

Jim Gualdoni, Respiratory Manager, Medical West

Case Study: Apria Healthcare Group Inc.

Introduction

This case study of Apria Healthcare Group Inc. is based on a November 2014 survey of Philips Respironics: Trilogy Ventilator customers by TechValidate, a 3rd-party research service.

“We have started a new NIV program promoting AVAPS AE for our COPD with chronic respiratory failure or neuromuscular patients and the Trilogy is easy to explain and transport at physician in-services. I think it’s a great ventilator!”

Challenges

  • Purchased the Trilogy because of:
    • AVAPS AE specifically for the COPD population
  • Looking to achieve the following challenges with the Trilogy:
    • New NIV program

Use Case

  • 50-74% of their Trilogy patients are diagnosed with COPD.
  • Evaluated the following alternative devices before purchasing the Trilogy:
    • LTV
  • AVAPS is the most commonly prescribed mode for Non-Invasive Ventilation COPD patients.

Results

  • Patients realized the following benefits with the Trilogy:
    • Provided ease of use
    • Improved quality of life
    • Improved clinical efficacy
    • Reduced hospital readmissions
  • Rates the following Trilogy capabilities on how differentiated they are from the competition:
    • Clinical performance: highly differentiated
    • Ease of use: very highly differentiated
    • Reliability: highly differentiated
    • Patient satisfaction: highly differentiated
    • Ventilation modes (AVAPS AE): highly differentiated


More to Explore



About Philips Respironics: Trilogy Ventilator

Philips Respironics, a global leader in the Sleep and Respiratory markets, is passionate about providing solutions that lead to healthier patients, healthier practices, and healthier businesses. They believe that effective sleep and respiratory management empowers patients to rediscover confidence and the freedom to live a fulfilling life by restoring their ability to sleep and breathe naturally.

Philips Respironics: Trilogy Ventilator Website   Philips Healthcare Website